MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Phase 3 Clinical Trials

  • Home
  • Phase 3 Clinical Trials
Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials
Posted inAllergy & Immunology Clinical Updates Dermatology news

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials

Posted by By MedXY 08/17/2026
Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.
Read More
Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: Clinical Advances and Therapeutic Implications
Posted innews Oncology Specialties

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: Clinical Advances and Therapeutic Implications

Posted by By MedXY 09/10/2025
Phase 3 trials demonstrate that encapsulated cell therapy NT-501 significantly slows photoreceptor loss in MacTel, marking a promising disease-modifying approach with an acceptable safety profile.
Read More
  • Enhanced Risk Stratification for Pediatric Tracheostomy Hospitalizations: Evaluating a Novel Tracheostomy-Specific Tier System
  • Long-Term Outcomes of Dysphagia Following Type I Laryngeal Cleft Repair in Children
  • Inadvertent Parathyroidectomy During Thyroid Surgery: Incidence, Risk Factors, and Clinical Implications
  • Understanding Surgical Faculty Retention: Key Factors Influencing Their Decision to Stay or Leave
  • Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-Up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top